|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
1R43CA210817-01A1
|
$152,589
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Minimally invasive image-guided tumor ablation in an oncogenic pig model
|
5R21CA195433-02
|
$266,380
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S2
|
$50,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-07
|
$375,250
|
DIPERSIO, C. MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
1R01CA216248-01
|
$565,675
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-15
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Signal transduction regulating tumor cell dissemination
|
5R01CA150344-29
|
$396,625
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The role of tunneling nanotubes as a novel mode of tumor cell-macrophage communication
|
5F99CA212451-02
|
$44,044
|
HANNA, SAMER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Roles of formins in breast cancer invasion
|
5R21CA205262-02
|
$217,935
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
5F31CA183493-04
|
$49,044
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The Metastatic Cascade: Macrophages Lead the Way
|
5R01CA172451-06
|
$439,400
|
POLLARD, JEFFREY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-02
|
$382,013
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
2R44CA183362-02A1
|
$822,075
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
Establishment of a patient-like mouse models of soft-tissue sarcoma sub-types
|
1R43CA213649-01
|
$224,700
|
HOFFMAN, ROBERT
|
ANTICANCER, INC.
|
|
Arizona Cancer and Evolution Center (ACE)
|
1U54CA217376-01A1
|
$1,906,167
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer
|
5R44CA203199-02
|
$402,226
|
TAYLOR, IAN
|
ARVINAS, INC.
|
|
P53 inactivation on MDSC development and tumor progression
|
5R01CA169133-05
|
$315,400
|
CUI, YAN
|
AUGUSTA UNIVERSITY
|
|
Role of SLC13A3 in Renal Cell Carcinoma
|
5F31CA210612-02
|
$33,744
|
JORDAN, ANDRE
|
AUGUSTA UNIVERSITY
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-08
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-09
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-04
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-05
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-04
|
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-05
|
$341,059
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Improving pathologic nodal staging of resected lung cancer
|
2R01CA172253-06
|
$499,347
|
OSAROGIAGBON, RAYMOND
|
BAPTIST MEMORIAL HOSPITAL - TIPTON
|
|
DACH1/Eya Cell fate determination factor and mammary tumorigenesis
|
7R01CA132115-08
|
$428,056
|
PESTELL, RICHARD
|
BARUCH S. BLUMBERG INSTITUTE
|
|
Risk Prediction for ER Negative Breast Cancer Recurrence
|
5R01CA172511-05
|
$593,132
|
BONDY, MELISSA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Investigating the mechanisms of CD44s splice isoform in breast cancer metastasis
|
5R01CA182467-05
|
$328,888
|
CHENG, CHONGHUI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis
|
5R01CA168717-05
|
$323,700
|
ELEFTERIOU, FLORENT
|
BAYLOR COLLEGE OF MEDICINE
|
|
ALK causes TGF-beta insensitivity in lung cancer cells
|
5R21CA209007-02
|
$206,843
|
FENG, XIN-HUA
|
BAYLOR COLLEGE OF MEDICINE
|
|
MECHANISMS OF AR-ER COLLABORATION IN HORMONE RESISTANCE AND METASTASIS OF BREAST CANCER
|
1R01CA207270-01A1
|
$362,569
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integration of Predictive Biomarkers of Hormone Resistance in Breast Cancer
|
5R01CA072038-19
|
$320,963
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Epigenomic reprogramming driven by mutant ER? in metastatic breast cancer
|
5F31CA210385-02
|
$43,993
|
GATES, LEAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Germ Cell Gene TDRD1 As A Novel Prostate Cancer Biomarker
|
1R01CA211861-01A1
|
$362,569
|
HE, BIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mitochondrial DNA copy number and fat metabolism in triple negative breast cancer
|
1R03CA212816-01
|
$79,250
|
KAIPPARETTU, BENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis
|
1R01CA204926-01A1
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
The cell of origin of breast cancer metastasis
|
5R21CA202227-02
|
$206,843
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
1R01CA215452-01
|
$362,569
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-01S1
|
$14,309
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-02S1
|
$7,156
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|